Medicines for pediatric oncology: can we overcome the failure to deliver?

ISSN： 1751-2433

Source： Expert Review of Clinical Pharmacology, Vol.5, Iss.5, 2012-09, pp. : 493-495

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Corticosteroid Avoidance in Pediatric Renal Transplantation: Can it Be Achieved?

By Jayakumar R. Vidhun Minnie M. Sarwal

Pediatric Drugs, Vol. 6, Iss. 5, 2004-01 ,pp. : 273-287

Adis International

Access to resources Recommend Favorite

Drugs, Heart Failure and Quality of Life: What Are We Achieving? What Should We Be Trying to Achieve?

By Doba N. Tomiyama H. Nakayama T.

Drugs & Aging, Vol. 14, Iss. 3, 1999-03 ,pp. : 153-163

Adis International

Access to resources Recommend Favorite

Personalised medicines, according to genotype?

Inpharma, Vol. 1, Iss. 1374, 2003-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Prevention and Pharmacovigilance: What Should We Do, What Can We Do?

By Edwards I. Ralph

Drug Safety, Vol. 35, Iss. 2, 2012-02 ,pp. : 87-90

Adis International

Access to resources Recommend Favorite

Should -Blockers be Used for the Treatment of Pediatric Patients with Chronic Heart Failure?

By Bruns L.A.

Pediatric Drugs, Vol. 4, Iss. 12, 2002-01 ,pp. : 771-778

Adis International

Access to resources Recommend Favorite